p tfeb Search Results


phospho-tfeb(ser142) polyclonal antibody  (Bioss)
94
Bioss phospho-tfeb(ser142) polyclonal antibody
Phospho Tfeb(Ser142) Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phospho-tfeb(ser142) polyclonal antibody/product/Bioss
Average 94 stars, based on 1 article reviews
phospho-tfeb(ser142) polyclonal antibody - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
p-tfeb antibody  (Affinity Biosciences)
90
Affinity Biosciences p-tfeb antibody
P Tfeb Antibody, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p-tfeb antibody/product/Affinity Biosciences
Average 90 stars, based on 1 article reviews
p-tfeb antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
antibodies against p-tfeb (ser221)  (Affinity Biosciences)
90
Affinity Biosciences antibodies against p-tfeb (ser221)
CHBP attenuates pyroptosis after SCI. (A) Images (20 × ) of spinal cord slices from the SCI + CHBP, SCI and sham groups on day 3 after SCI following incubation <t>with</t> <t>antibodies</t> against Caspase-1/NeuN (scale bar = 25 μm). (B) Quantitation of the average OD of Caspase-1 in neurons after SCI. (C) Images (20 × ) of spinal cord slices from the SCI + CHBP, SCI and sham groups on day 3 after SCI following incubation with antibodies against <t>GSDMD/NeuN</t> (scale bar = 25 μm). (D) Quantitation of the average OD of GSDMD in neurons after SCI. (E) ODs of the NLRP1, IL-1β, ASC, Caspase-1, IL-18, NLRP3, and GSDMD bands in the indicated groups on day 3 after SCI. The blots were subjected to the same experimental conditions, and cropped images of the blots are shown. (F) The expression levels of NLRP1, IL-1β, GSDMD, NLRP3, ASC, Caspase-1, and IL-18 in each group were quantified. The data are presented as the mean ± SEM; n = 6 per group. * p < 0.05 and ** p < 0.01 versus the sham group. # p < 0.05 and ## p < 0.01 versus the SCI group. Statistical analysis was performed using two-way ANOVA followed by Tukey's multiple comparison test.
Antibodies Against P Tfeb (Ser221), supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against p-tfeb (ser221)/product/Affinity Biosciences
Average 90 stars, based on 1 article reviews
antibodies against p-tfeb (ser221) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
p-tfeb (s142) rabbit polyclonal antibody  (Merck KGaA)
90
Merck KGaA p-tfeb (s142) rabbit polyclonal antibody
CHBP attenuates pyroptosis after SCI. (A) Images (20 × ) of spinal cord slices from the SCI + CHBP, SCI and sham groups on day 3 after SCI following incubation <t>with</t> <t>antibodies</t> against Caspase-1/NeuN (scale bar = 25 μm). (B) Quantitation of the average OD of Caspase-1 in neurons after SCI. (C) Images (20 × ) of spinal cord slices from the SCI + CHBP, SCI and sham groups on day 3 after SCI following incubation with antibodies against <t>GSDMD/NeuN</t> (scale bar = 25 μm). (D) Quantitation of the average OD of GSDMD in neurons after SCI. (E) ODs of the NLRP1, IL-1β, ASC, Caspase-1, IL-18, NLRP3, and GSDMD bands in the indicated groups on day 3 after SCI. The blots were subjected to the same experimental conditions, and cropped images of the blots are shown. (F) The expression levels of NLRP1, IL-1β, GSDMD, NLRP3, ASC, Caspase-1, and IL-18 in each group were quantified. The data are presented as the mean ± SEM; n = 6 per group. * p < 0.05 and ** p < 0.01 versus the sham group. # p < 0.05 and ## p < 0.01 versus the SCI group. Statistical analysis was performed using two-way ANOVA followed by Tukey's multiple comparison test.
P Tfeb (S142) Rabbit Polyclonal Antibody, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p-tfeb (s142) rabbit polyclonal antibody/product/Merck KGaA
Average 90 stars, based on 1 article reviews
p-tfeb (s142) rabbit polyclonal antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


CHBP attenuates pyroptosis after SCI. (A) Images (20 × ) of spinal cord slices from the SCI + CHBP, SCI and sham groups on day 3 after SCI following incubation with antibodies against Caspase-1/NeuN (scale bar = 25 μm). (B) Quantitation of the average OD of Caspase-1 in neurons after SCI. (C) Images (20 × ) of spinal cord slices from the SCI + CHBP, SCI and sham groups on day 3 after SCI following incubation with antibodies against GSDMD/NeuN (scale bar = 25 μm). (D) Quantitation of the average OD of GSDMD in neurons after SCI. (E) ODs of the NLRP1, IL-1β, ASC, Caspase-1, IL-18, NLRP3, and GSDMD bands in the indicated groups on day 3 after SCI. The blots were subjected to the same experimental conditions, and cropped images of the blots are shown. (F) The expression levels of NLRP1, IL-1β, GSDMD, NLRP3, ASC, Caspase-1, and IL-18 in each group were quantified. The data are presented as the mean ± SEM; n = 6 per group. * p < 0.05 and ** p < 0.01 versus the sham group. # p < 0.05 and ## p < 0.01 versus the SCI group. Statistical analysis was performed using two-way ANOVA followed by Tukey's multiple comparison test.

Journal: Redox Biology

Article Title: Cyclic helix B peptide alleviates proinflammatory cell death and improves functional recovery after traumatic spinal cord injury

doi: 10.1016/j.redox.2023.102767

Figure Lengend Snippet: CHBP attenuates pyroptosis after SCI. (A) Images (20 × ) of spinal cord slices from the SCI + CHBP, SCI and sham groups on day 3 after SCI following incubation with antibodies against Caspase-1/NeuN (scale bar = 25 μm). (B) Quantitation of the average OD of Caspase-1 in neurons after SCI. (C) Images (20 × ) of spinal cord slices from the SCI + CHBP, SCI and sham groups on day 3 after SCI following incubation with antibodies against GSDMD/NeuN (scale bar = 25 μm). (D) Quantitation of the average OD of GSDMD in neurons after SCI. (E) ODs of the NLRP1, IL-1β, ASC, Caspase-1, IL-18, NLRP3, and GSDMD bands in the indicated groups on day 3 after SCI. The blots were subjected to the same experimental conditions, and cropped images of the blots are shown. (F) The expression levels of NLRP1, IL-1β, GSDMD, NLRP3, ASC, Caspase-1, and IL-18 in each group were quantified. The data are presented as the mean ± SEM; n = 6 per group. * p < 0.05 and ** p < 0.01 versus the sham group. # p < 0.05 and ## p < 0.01 versus the SCI group. Statistical analysis was performed using two-way ANOVA followed by Tukey's multiple comparison test.

Article Snippet: Antibodies against NLRP1, MLKL, GSDMD and p-TFEB (Ser221) were obtained from Affinity Biosciences (USA; Cat# DF13187, Cat# DF7412, Cat# AF4013, and Cat# AF3708, respectively).

Techniques: Incubation, Quantitation Assay, Expressing, Comparison

CHBP promotes autophagy to inhibit pyroptosis and necroptosis after SCI. (A) Images (20 × ) of spinal cord slices from the mentioned groups on day 3 after SCI following incubation with antibodies against p62/NeuN and LC3/NeuN (scale bar = 25 μm). (B–C) Quantitation of the average OD of p62 and the number of LC3II puncta in each neuron in the abovementioned groups. (D) ODs of the p62, LC3II, Beclin-1, VPS34, and CTSD bands in the indicated groups on day 3 after SCI. (E) The expression levels of p62, LC3II, Beclin-1, VPS34, and CTSD in the abovementioned groups were quantified. (F) Images (20 × ) of spinal cord slices from the aforementioned groups on day 3 after SCI following incubation with antibodies against Caspase-1/NeuN and GSDMD/NeuN (scale bar = 25 μm). (G–H) Quantitation of the average ODs of Caspase-1 and GSDMD in neurons after SCI. (I) ODs of the NLRP1, IL-1β, NLRP3, Caspase-1, ASC, GSDMD, and IL-18 bands in the indicated groups on day 3 after SCI. (J) The expression levels of NLRP1, IL-1β, NLRP3, Caspase-1, ASC, GSDMD, and IL-18 in the abovementioned groups were quantified. (K) Images (20 × ) of spinal cord slices from the abovementioned groups on day 1 after SCI following incubation with antibodies against RIPK1/NeuN and RIPK3/NeuN (scale bar = 25 μm). (L–M) Quantitation of the ODs of RIPK1 and RIPK3 in neurons after SCI. (N) ODs of the RIPK1, MLKL, RIPK3, and C-Caspase-8 bands in the indicated groups on day 1 after SCI. (O) The expression levels of RIPK1, MLKL, RIPK3, and C-Caspase-8 in the abovementioned groups were quantified. The data are presented as the average ± SEM; n = 6 each group. @ p < 0.05 and @@ p < 0.01 versus the SCI + CHBP group. Statistical analysis was performed using an unpaired t -test.

Journal: Redox Biology

Article Title: Cyclic helix B peptide alleviates proinflammatory cell death and improves functional recovery after traumatic spinal cord injury

doi: 10.1016/j.redox.2023.102767

Figure Lengend Snippet: CHBP promotes autophagy to inhibit pyroptosis and necroptosis after SCI. (A) Images (20 × ) of spinal cord slices from the mentioned groups on day 3 after SCI following incubation with antibodies against p62/NeuN and LC3/NeuN (scale bar = 25 μm). (B–C) Quantitation of the average OD of p62 and the number of LC3II puncta in each neuron in the abovementioned groups. (D) ODs of the p62, LC3II, Beclin-1, VPS34, and CTSD bands in the indicated groups on day 3 after SCI. (E) The expression levels of p62, LC3II, Beclin-1, VPS34, and CTSD in the abovementioned groups were quantified. (F) Images (20 × ) of spinal cord slices from the aforementioned groups on day 3 after SCI following incubation with antibodies against Caspase-1/NeuN and GSDMD/NeuN (scale bar = 25 μm). (G–H) Quantitation of the average ODs of Caspase-1 and GSDMD in neurons after SCI. (I) ODs of the NLRP1, IL-1β, NLRP3, Caspase-1, ASC, GSDMD, and IL-18 bands in the indicated groups on day 3 after SCI. (J) The expression levels of NLRP1, IL-1β, NLRP3, Caspase-1, ASC, GSDMD, and IL-18 in the abovementioned groups were quantified. (K) Images (20 × ) of spinal cord slices from the abovementioned groups on day 1 after SCI following incubation with antibodies against RIPK1/NeuN and RIPK3/NeuN (scale bar = 25 μm). (L–M) Quantitation of the ODs of RIPK1 and RIPK3 in neurons after SCI. (N) ODs of the RIPK1, MLKL, RIPK3, and C-Caspase-8 bands in the indicated groups on day 1 after SCI. (O) The expression levels of RIPK1, MLKL, RIPK3, and C-Caspase-8 in the abovementioned groups were quantified. The data are presented as the average ± SEM; n = 6 each group. @ p < 0.05 and @@ p < 0.01 versus the SCI + CHBP group. Statistical analysis was performed using an unpaired t -test.

Article Snippet: Antibodies against NLRP1, MLKL, GSDMD and p-TFEB (Ser221) were obtained from Affinity Biosciences (USA; Cat# DF13187, Cat# DF7412, Cat# AF4013, and Cat# AF3708, respectively).

Techniques: Incubation, Quantitation Assay, Expressing

TFEB inhibition reverses the suppressive effects of CHBP on pyroptosis and necroptosis following SCI. (A) Analysis GSDMD and NeuN colocalization in spinal cord lesions on day 3 after SCI by IF staining (scale bar = 25 μm). (B) Average OD of GSDMD in neurons in the spinal cord lesion. (C) WB analysis of IL-18, IL-1β, GSDMD, Caspase-1, ASC, NLRP3, and NLRP1 expression levels in each group on day 3 after SCI. (D) The ODs of IL-18, IL-1β, GSDMD, Caspase-1, ASC, NLRP3, and NLRP1 in the different groups were quantified. (E) Analysis of RIPK1 and NeuN colocalization in the spinal cord lesion on day 1 after SCI by IF staining (scale bar = 25 μm). (F) Quantification of the OD of RIPK1 in neurons in the spinal cord lesion. (G) WB analysis of C-Caspase-8, MLKL, RIPK3, and RIPK1 expression in the three groups on day 1 after SCI. (H) The ODs of C-Caspase-8, MLKL, RIPK3, and RIPK1 in the different groups were quantified. The data are expressed as the mean ± SEM; n = 6 per group. @ p < 0.05 and @@ p < 0.01 versus the SCI + CHBP group. & p < 0.05 and && p < 0.01 versus the SCI + CHBP + scrambled shRNA group. Statistical analysis was performed using two-way ANOVA followed by Tukey's multiple comparison test.

Journal: Redox Biology

Article Title: Cyclic helix B peptide alleviates proinflammatory cell death and improves functional recovery after traumatic spinal cord injury

doi: 10.1016/j.redox.2023.102767

Figure Lengend Snippet: TFEB inhibition reverses the suppressive effects of CHBP on pyroptosis and necroptosis following SCI. (A) Analysis GSDMD and NeuN colocalization in spinal cord lesions on day 3 after SCI by IF staining (scale bar = 25 μm). (B) Average OD of GSDMD in neurons in the spinal cord lesion. (C) WB analysis of IL-18, IL-1β, GSDMD, Caspase-1, ASC, NLRP3, and NLRP1 expression levels in each group on day 3 after SCI. (D) The ODs of IL-18, IL-1β, GSDMD, Caspase-1, ASC, NLRP3, and NLRP1 in the different groups were quantified. (E) Analysis of RIPK1 and NeuN colocalization in the spinal cord lesion on day 1 after SCI by IF staining (scale bar = 25 μm). (F) Quantification of the OD of RIPK1 in neurons in the spinal cord lesion. (G) WB analysis of C-Caspase-8, MLKL, RIPK3, and RIPK1 expression in the three groups on day 1 after SCI. (H) The ODs of C-Caspase-8, MLKL, RIPK3, and RIPK1 in the different groups were quantified. The data are expressed as the mean ± SEM; n = 6 per group. @ p < 0.05 and @@ p < 0.01 versus the SCI + CHBP group. & p < 0.05 and && p < 0.01 versus the SCI + CHBP + scrambled shRNA group. Statistical analysis was performed using two-way ANOVA followed by Tukey's multiple comparison test.

Article Snippet: Antibodies against NLRP1, MLKL, GSDMD and p-TFEB (Ser221) were obtained from Affinity Biosciences (USA; Cat# DF13187, Cat# DF7412, Cat# AF4013, and Cat# AF3708, respectively).

Techniques: Inhibition, Staining, Expressing, shRNA, Comparison

CHBP stimulates TFEB activity via the AMPK-mTOR pathway and AMPK-FOXO3a-SPK2-CARM1 signalling pathway after SCI. (A) WB analysis of the cytoplasmic expression of p-TFEB (Ser221), AMPK, p-AMPK, mTOR, and p-mTOR normalized to the expression of GAPDH as an internal control on day 3 after SCI and the nuclear expression of TFEB normalized to the expression of histone H3 as an internal control on day 3 after SCI. (B) Densitometric quantification of the p-mTOR, mTOR, p-AMPK, AMPK, p-TFEB (Ser221), and nuclear TFEB bands. (C) WB analysis of the nuclear expression of CARM1, SKP2, FOXO3a, p-FOXO3a, p-AMPK, and AMPK normalized to the expression of Histone H3 as an internal control on day 3 after SCI. (D) Densitometric quantification of the CARM1, SKP2, FOXO3a, p-FOXO3a, p-AMPK, and AMPK bands. (E) The nuclear CARM1-TFEB complex in the indicated groups was detected by immunoprecipitation on day 3 after SCI. (F) The densities of the TFEB and CARM1 bands in E normalized to the density of the band for H3 as a loading control. (G) WB analysis of RIPK1, RIPK3, GSDMD, and Caspase-1 expression levels at 1 dpi and 3 dpi and the expression levels of LC3II and p62 on day 3 after SCI in the three groups. (H) The densities of the LC3II, p62, RIPK1, RIPK3, GSDMD, and Caspase-1 bands in G normalized to the density of the GAPDH band. The data are presented as the mean ± SEM; n = 6 per group. * p < 0.05 and ** p < 0.01 versus the SCI group. @ p < 0.05 and @@ p < 0.01 versus the SCI + CHBP group. ns, not significant. Statistical analysis was performed using two-way ANOVA followed by Tukey's multiple comparison test.

Journal: Redox Biology

Article Title: Cyclic helix B peptide alleviates proinflammatory cell death and improves functional recovery after traumatic spinal cord injury

doi: 10.1016/j.redox.2023.102767

Figure Lengend Snippet: CHBP stimulates TFEB activity via the AMPK-mTOR pathway and AMPK-FOXO3a-SPK2-CARM1 signalling pathway after SCI. (A) WB analysis of the cytoplasmic expression of p-TFEB (Ser221), AMPK, p-AMPK, mTOR, and p-mTOR normalized to the expression of GAPDH as an internal control on day 3 after SCI and the nuclear expression of TFEB normalized to the expression of histone H3 as an internal control on day 3 after SCI. (B) Densitometric quantification of the p-mTOR, mTOR, p-AMPK, AMPK, p-TFEB (Ser221), and nuclear TFEB bands. (C) WB analysis of the nuclear expression of CARM1, SKP2, FOXO3a, p-FOXO3a, p-AMPK, and AMPK normalized to the expression of Histone H3 as an internal control on day 3 after SCI. (D) Densitometric quantification of the CARM1, SKP2, FOXO3a, p-FOXO3a, p-AMPK, and AMPK bands. (E) The nuclear CARM1-TFEB complex in the indicated groups was detected by immunoprecipitation on day 3 after SCI. (F) The densities of the TFEB and CARM1 bands in E normalized to the density of the band for H3 as a loading control. (G) WB analysis of RIPK1, RIPK3, GSDMD, and Caspase-1 expression levels at 1 dpi and 3 dpi and the expression levels of LC3II and p62 on day 3 after SCI in the three groups. (H) The densities of the LC3II, p62, RIPK1, RIPK3, GSDMD, and Caspase-1 bands in G normalized to the density of the GAPDH band. The data are presented as the mean ± SEM; n = 6 per group. * p < 0.05 and ** p < 0.01 versus the SCI group. @ p < 0.05 and @@ p < 0.01 versus the SCI + CHBP group. ns, not significant. Statistical analysis was performed using two-way ANOVA followed by Tukey's multiple comparison test.

Article Snippet: Antibodies against NLRP1, MLKL, GSDMD and p-TFEB (Ser221) were obtained from Affinity Biosciences (USA; Cat# DF13187, Cat# DF7412, Cat# AF4013, and Cat# AF3708, respectively).

Techniques: Activity Assay, Expressing, Control, Immunoprecipitation, Comparison